Check-Cap Ltd. Ord (CHEK) 2.06 $CHEK
Check-Cap to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
PR Newswire - Wed Sep 07, 6:00AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:30pm ET in New York City.
CHEK: 2.06 (+0.04)
Check-Cap Reports Second Quarter 2016 Financial Results
PR Newswire - Mon Aug 15, 3:01PM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the second quarter and six months ended June 30, 2016.
CHEK: 2.06 (+0.04)
Check-Cap Ltd. Announces $5.9 Million Financing
PR Newswire - Mon Aug 08, 7:26AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million. The Securities Purchase Agreement provides for gross proceeds of $5.9 million, which is comprised of 643,614 ordinary shares, at a purchase price of $1.90 per share and 2,514,281 pre-funded warrants in lieu of ordinary shares, at a purchase price of $1.85 per warrant, which are exercisable for a nominal exercise price (approximately $0.05 per share). In the event that all warrants are exercised, the total gross proceeds to the Company for this financing would be $6.0 million.
CHEK: 2.06 (+0.04)
Check-Cap Announces Agreement with GE Healthcare for X-Ray Capsule Manufacturing Collaboration
PR Newswire - Thu Aug 04, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has entered into an agreement with GE Healthcare to develop and validate high-volume manufacturing for X-ray source production and assembly into Check-Cap's capsule. Upon successful completion, the parties may discuss collaboration on execution of a high-volume manufacturing facility and distribution of the Check-Cap system.
CHEK: 2.06 (+0.04)
Check-Cap Awarded $1.25 Million Grant for 2016 From Israel's Office of the Chief Scientist
PR Newswire - Tue Aug 02, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Israel's Office of the Chief Scientist (the "OCS" has awarded the Company a grant of NIS 4.8 million (approximately equivalent to $1.25 million based on the current exchange rate) for 2016. Charged with execution of government policy for support of R&D, the goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel's scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally.
CHEK: 2.06 (+0.04)
A Win-Win With Check Into Cash: Cash for You and Cash for Kids
PR Newswire - Tue May 31, 11:46AM CDT
This month, don't miss Check Into Cash's Cash For Kids Facebook giveaway benefitting St. Jude Children's Research Hospital. Check Into Cash will match June's $500 giveaway prize with a $500 donation to St. Jude. St. Jude works to advance cures and prevention for pediatric catastrophic diseases, such as cancer, through research and treatment.
CHEK: 2.06 (+0.04)
Check-Cap Announces Preliminary Data Evaluating its Preparation-Free Colon Screening Capsule
PR Newswire - Wed May 25, 7:49AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that preliminary data from pre-clinical and clinical studies were discussed in a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" during Digestive Disease Week® (DDW) 2016, taking place in San Diego from May 21-24.
CHEK: 2.06 (+0.04)
Check-Cap Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 19, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the three months ended March 31, 2016.
CHEK: 2.06 (+0.04)
Check-Cap Announces Presentation Evaluating Ingestible Capsule for Preparation-Free Colorectal Cancer Screening at Digestive Disease Week® 2016
PR Newswire - Tue May 17, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" will be delivered at Digestive Disease Week® (DDW) 2016. The conference is taking place in San Diego from May 21-24.
CHEK: 2.06 (+0.04)
Check-Cap Announces the Publication of Preliminary Clinical Data on its Preparation-Free Colon Screening Capsule in Gut
PR Newswire - Mon Dec 14, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that data related to its clinical studies have been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology.
CHEK: 2.06 (+0.04)
Check-Cap CEO to Present at LD Micro Main Event on December 2, 2015
PR Newswire - Wed Nov 25, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Check-Cap's Chief Executive Officer, will present at the LD Micro 8th Annual Main Event on December 2, 2015 in Los Angeles, CA.
CHEK: 2.06 (+0.04)
Bradley County's Official Halloween Goblin Returns for the 2015 Block Party
Marketwired - Mon Oct 26, 8:02AM CDT
As Halloween draws near, anticipation is building in Cleveland, Tenn. around the 28th annual Halloween Block Party and the spooky appearance of Tall Betsy, Bradley County's official Halloween goblin. Tall Betsy, a 7½-foot tall goblin rumored to reside in Fort Hill Cemetery, will make her appearance from 7:30-8 p.m. The Halloween Block Party takes place from 5-10 p.m. on Saturday, October 31 in downtown Cleveland.
CHEK: 2.06 (+0.04)
Check-Cap Featured at the World Endoscopy Organization Colorectal Cancer Screening Committee Meeting
PR Newswire - Mon Oct 26, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that the Check-Cap system was highlighted at the World Endoscopy Organization Colorectal Cancer Screening Committee (WEO CRC SC) Meeting which took place on October 23 in Barcelona, Spain.
CHEK: 2.06 (+0.04)
Check-Cap incurs lower net loss of USD48,000 for Q3 2015
M2 - Fri Oct 23, 5:43AM CDT
Medical diagnostics company Check-Cap (Nasdaq:CHEK)(Nasdaq:CHEKW) stated on Thursday its net loss of USD48,000 for the third quarter ended 30 September 2015.
CHEKW: 0.60 (-0.19), CHEK: 2.06 (+0.04)
Check-Cap Reports Third Quarter 2015 Financial Results
PR Newswire - Thu Oct 22, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap" (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced its financial results for the third quarter and nine months ended September 30, 2015. The Company also announced that it will hold its 2015 Annual General Meeting of Shareholders on December 1, 2015.
CHEK: 2.06 (+0.04)
Check-Cap Announces New Data Demonstrating Safety and Detection of Polyps in Clinical Study Evaluating Preparation-Free Colorectal Cancer Screening Capsule
PR Newswire - Tue Oct 20, 5:10AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon. Results will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015.
CHEK: 2.06 (+0.04)
Check Into Cash Launches #CheckIntoPink Campaign for Breast Cancer Awareness Month
Marketwired - Thu Oct 01, 6:01AM CDT
Check Into Cash, a national leader in alternative financial services, launches its #CheckIntoPink social campaign today to help spread knowledge about breast cancer. This is the second year in a row that Check Into Cash has participated in Breast Cancer Awareness Month to raise support for women's health. The campaign, which will run throughout October, will lead the audience to CheckIntoCash.com/GoPink, an informational page featuring tips and other educational resources.
CHEK: 2.06 (+0.04)
Check-Cap Announces Appointment of William Densel as Chief Executive Officer and Director
PR Newswire - Thu Aug 13, 8:30AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today the appointment of William (Bill) Densel as Chief Executive Officer. The terms of Mr. Densel's engagement as Chief Executive Officer were approved at an extraordinary general meeting of shareholders held today. In addition, Check-Cap's Board of Directors elected Mr. Densel as a director to fill a vacancy on the Board, to serve in such office until the next annual general meeting of shareholders, effective as of the approval of the terms of his engagement as Chief Executive Officer by the Company's shareholders.
CHEK: 2.06 (+0.04)
Check-Cap to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016
PR Newswire - Wed Sep 07, 6:00AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016 at 5:30pm ET in New York City.
CHEK: 2.06 (+0.04)
Check-Cap Reports Second Quarter 2016 Financial Results
PR Newswire - Mon Aug 15, 3:01PM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the second quarter and six months ended June 30, 2016. CHEK: 2.06 (+0.04)
Check-Cap Ltd. Announces $5.9 Million Financing
PR Newswire - Mon Aug 08, 7:26AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million. The Securities Purchase Agreement provides for gross proceeds of $5.9 million, which is comprised of 643,614 ordinary shares, at a purchase price of $1.90 per share and 2,514,281 pre-funded warrants in lieu of ordinary shares, at a purchase price of $1.85 per warrant, which are exercisable for a nominal exercise price (approximately $0.05 per share). In the event that all warrants are exercised, the total gross proceeds to the Company for this financing would be $6.0 million. CHEK: 2.06 (+0.04)
Check-Cap Announces Agreement with GE Healthcare for X-Ray Capsule Manufacturing Collaboration
PR Newswire - Thu Aug 04, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced it has entered into an agreement with GE Healthcare to develop and validate high-volume manufacturing for X-ray source production and assembly into Check-Cap's capsule. Upon successful completion, the parties may discuss collaboration on execution of a high-volume manufacturing facility and distribution of the Check-Cap system. CHEK: 2.06 (+0.04)
Check-Cap Awarded $1.25 Million Grant for 2016 From Israel's Office of the Chief Scientist
PR Newswire - Tue Aug 02, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Israel's Office of the Chief Scientist (the "OCS" has awarded the Company a grant of NIS 4.8 million (approximately equivalent to $1.25 million based on the current exchange rate) for 2016. Charged with execution of government policy for support of R&D, the goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israel's scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D and encouraging R&D collaboration both nationally and internationally. CHEK: 2.06 (+0.04)
A Win-Win With Check Into Cash: Cash for You and Cash for Kids
PR Newswire - Tue May 31, 11:46AM CDT
This month, don't miss Check Into Cash's Cash For Kids Facebook giveaway benefitting St. Jude Children's Research Hospital. Check Into Cash will match June's $500 giveaway prize with a $500 donation to St. Jude. St. Jude works to advance cures and prevention for pediatric catastrophic diseases, such as cancer, through research and treatment.
CHEK: 2.06 (+0.04)
Check-Cap Announces Preliminary Data Evaluating its Preparation-Free Colon Screening Capsule
PR Newswire - Wed May 25, 7:49AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that preliminary data from pre-clinical and clinical studies were discussed in a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" during Digestive Disease Week® (DDW) 2016, taking place in San Diego from May 21-24. CHEK: 2.06 (+0.04)
Check-Cap Reports First Quarter 2016 Financial Results
PR Newswire - Thu May 19, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the three months ended March 31, 2016. CHEK: 2.06 (+0.04)
Check-Cap Announces Presentation Evaluating Ingestible Capsule for Preparation-Free Colorectal Cancer Screening at Digestive Disease Week® 2016
PR Newswire - Tue May 17, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced a podium presentation entitled "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening" will be delivered at Digestive Disease Week® (DDW) 2016. The conference is taking place in San Diego from May 21-24. CHEK: 2.06 (+0.04)
Check-Cap Announces the Publication of Preliminary Clinical Data on its Preparation-Free Colon Screening Capsule in Gut
PR Newswire - Mon Dec 14, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that data related to its clinical studies have been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology. CHEK: 2.06 (+0.04)
Check-Cap CEO to Present at LD Micro Main Event on December 2, 2015
PR Newswire - Wed Nov 25, 6:00AM CST
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that Bill Densel, Check-Cap's Chief Executive Officer, will present at the LD Micro 8th Annual Main Event on December 2, 2015 in Los Angeles, CA. CHEK: 2.06 (+0.04)
Bradley County's Official Halloween Goblin Returns for the 2015 Block Party
Marketwired - Mon Oct 26, 8:02AM CDT
As Halloween draws near, anticipation is building in Cleveland, Tenn. around the 28th annual Halloween Block Party and the spooky appearance of Tall Betsy, Bradley County's official Halloween goblin. Tall Betsy, a 7½-foot tall goblin rumored to reside in Fort Hill Cemetery, will make her appearance from 7:30-8 p.m. The Halloween Block Party takes place from 5-10 p.m. on Saturday, October 31 in downtown Cleveland.
CHEK: 2.06 (+0.04)
Check-Cap Featured at the World Endoscopy Organization Colorectal Cancer Screening Committee Meeting
PR Newswire - Mon Oct 26, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that the Check-Cap system was highlighted at the World Endoscopy Organization Colorectal Cancer Screening Committee (WEO CRC SC) Meeting which took place on October 23 in Barcelona, Spain. CHEK: 2.06 (+0.04)
Check-Cap incurs lower net loss of USD48,000 for Q3 2015
M2 - Fri Oct 23, 5:43AM CDT
Medical diagnostics company Check-Cap (Nasdaq:CHEK)(Nasdaq:CHEKW) stated on Thursday its net loss of USD48,000 for the third quarter ended 30 September 2015.
CHEKW: 0.60 (-0.19), CHEK: 2.06 (+0.04)
Check-Cap Reports Third Quarter 2015 Financial Results
PR Newswire - Thu Oct 22, 6:00AM CDT
Check-Cap Ltd. (the "Company" or "Check-Cap"
(NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced its financial results for the third quarter and nine months ended September 30, 2015. The Company also announced that it will hold its 2015 Annual General Meeting of Shareholders on December 1, 2015. CHEK: 2.06 (+0.04)
Check-Cap Announces New Data Demonstrating Safety and Detection of Polyps in Clinical Study Evaluating Preparation-Free Colorectal Cancer Screening Capsule
PR Newswire - Tue Oct 20, 5:10AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced new data demonstrating safety and polyp detection from a clinical study evaluating the company's non-invasive system for preparation-free examination of the colon. Results will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 16-21, 2015 and the United European Gastroenterology Week (UEGW) taking place October 24-28, 2015.
CHEK: 2.06 (+0.04)
Check Into Cash Launches #CheckIntoPink Campaign for Breast Cancer Awareness Month
Marketwired - Thu Oct 01, 6:01AM CDT
Check Into Cash, a national leader in alternative financial services, launches its #CheckIntoPink social campaign today to help spread knowledge about breast cancer. This is the second year in a row that Check Into Cash has participated in Breast Cancer Awareness Month to raise support for women's health. The campaign, which will run throughout October, will lead the audience to CheckIntoCash.com/GoPink, an informational page featuring tips and other educational resources.
CHEK: 2.06 (+0.04)
Check-Cap Announces Appointment of William Densel as Chief Executive Officer and Director
PR Newswire - Thu Aug 13, 8:30AM CDT
Check-Cap Ltd. (Nasdaq: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today the appointment of William (Bill) Densel as Chief Executive Officer. The terms of Mr. Densel's engagement as Chief Executive Officer were approved at an extraordinary general meeting of shareholders held today. In addition, Check-Cap's Board of Directors elected Mr. Densel as a director to fill a vacancy on the Board, to serve in such office until the next annual general meeting of shareholders, effective as of the approval of the terms of his engagement as Chief Executive Officer by the Company's shareholders.
CHEK: 2.06 (+0.04)
